Literature DB >> 19164447

Androgen modulation of coregulator expression in prostate cancer cells.

Hannelore V Heemers1, Kevin M Regan, Lucy J Schmidt, S Keith Anderson, Karla V Ballman, Donald J Tindall.   

Abstract

Aberrant coregulator expression that occurs during prostate cancer (PCa) progression correlates with poor prognosis and aggressive disease. This has been attributed to the ability to regulate androgen receptor-mediated transcription. We have shown previously that the androgenic milieu regulates the expression of the coactivators p300 and FHL2, with severe consequences for PCa cell proliferation and androgen receptor transcriptional activity. To determine the extent of androgen dependency of coregulator genes, we designed a cDNA-mediated annealing, selection, extension, and ligation RNA profiling array that probes the expression of 186 coregulators. Using this assay, we demonstrated androgen control over approximately 30% of coregulator genes in PCa cells. For a subset of 15 functionally diverse coregulators, androgen regulation was confirmed using real-time RT-PCR and immunoblotting. The extent, dose dependency, and kinetics by which androgens affect coregulator expression differed widely, indicating diverse molecular mechanisms underlying these effects. Moreover, differences in coregulator expression were observed between isogenic androgen-dependent and castration-recurrent PCa cells. Small interfering RNA-mediated changes in coregulator expression had profound effects on cell proliferation, which were most pronounced in castration-recurrent cells. Taken together, our integrated approach combining expression profiling, characterization of androgen-dependent coregulator expression, and validation of the importance of altered coregulator expression for cell proliferation identified several potential novel therapeutic targets for PCa treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164447      PMCID: PMC2667711          DOI: 10.1210/me.2008-0363

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  40 in total

1.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

Review 2.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Authors:  Ivan V Litvinov; Angelo M De Marzo; John T Isaacs
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

3.  Faster cyclic loess: normalizing RNA arrays via linear models.

Authors:  Karla V Ballman; Diane E Grill; Ann L Oberg; Terry M Therneau
Journal:  Bioinformatics       Date:  2004-05-27       Impact factor: 6.937

Review 4.  Androgen receptor coactivators and prostate cancer.

Authors:  Irina U Agoulnik; Nancy L Weigel
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells.

Authors:  Takehiko Segawa; Martin E Nau; Linda L Xu; Rao N Chilukuri; Mazen Makarem; Wei Zhang; Gyorgy Petrovics; Isabell A Sesterhenn; David G McLeod; Judd W Moul; Maryanne Vahey; Shiv Srivastava
Journal:  Oncogene       Date:  2002-12-12       Impact factor: 9.867

Review 6.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

7.  Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter.

Authors:  K B Cleutjens; C C van Eekelen; H A van der Korput; A O Brinkmann; J Trapman
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

8.  Digital expression profiles of the prostate androgen-response program.

Authors:  Nigel Clegg; Burak Eroglu; Camari Ferguson; Hugh Arnold; Alec Moorman; Peter S Nelson
Journal:  J Steroid Biochem Mol Biol       Date:  2002-01       Impact factor: 4.292

9.  The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes.

Authors:  Y Xue; J C Canman; C S Lee; Z Nie; D Yang; G T Moreno; M K Young; E D Salmon; W Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

10.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.

Authors:  Charles E Massie; Boris Adryan; Nuno L Barbosa-Morais; Andy G Lynch; Maxine G Tran; David E Neal; Ian G Mills
Journal:  EMBO Rep       Date:  2007-08-17       Impact factor: 8.807

View more
  38 in total

1.  Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Authors:  Lin Yang; Preethi Ravindranathan; Meera Ramanan; Payal Kapur; Stephen R Hammes; Jer-Tsong Hsieh; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2012-03-08

2.  miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.

Authors:  Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades
Journal:  Mol Endocrinol       Date:  2015-06-12

Review 3.  Translational and clinical implications of the genetic landscape of prostate cancer.

Authors:  Daniel E Spratt; Zachary S Zumsteg; Felix Y Feng; Scott A Tomlins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

4.  Identification of location and kinetically defined mechanism of cofactors and reporter genes in the cascade of steroid-regulated transactivation.

Authors:  John A Blackford; Chunhua Guo; Rong Zhu; Edward J Dougherty; Carson C Chow; S Stoney Simons
Journal:  J Biol Chem       Date:  2012-10-10       Impact factor: 5.157

Review 5.  Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors:  Nima Sharifi
Journal:  Endocrinology       Date:  2013-09-03       Impact factor: 4.736

6.  DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; Bingcheng Wang; Thomas J Kelley; David Danielpour
Journal:  Mol Endocrinol       Date:  2010-08-25

7.  PA1 protein, a new competitive decelerator acting at more than one step to impede glucocorticoid receptor-mediated transactivation.

Authors:  Zhenhuan Zhang; Yunguang Sun; Young-Wook Cho; Carson C Chow; S Stoney Simons
Journal:  J Biol Chem       Date:  2012-11-17       Impact factor: 5.157

8.  Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma.

Authors:  Jinxia Liu; Wenkai Ni; Mingbing Xiao; Feng Jiang; Runzhou Ni
Journal:  J Gastrointest Surg       Date:  2013-01-17       Impact factor: 3.452

Review 9.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 10.  The FHL2 regulation in the transcriptional circuitry of human cancers.

Authors:  Cyanne Ye Cao; Simon Wing-Fai Mok; Vincent Wing-Sang Cheng; Stephen Kwok-Wing Tsui
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.